Jazz Pharma’s blood cancer therapy Rylaze wins US approval
Rylaze has been specifically developed for patients who have developed hypersensitivity to E.coli-derived asparaginase
Read More
Tag: acute lymphoblastic leukaemia
NICE evidence request for Blincyto for acute lymphoblastic leukaemia
NICE has requested further evidence on Amgen’s Blincyto for the treatment of adults with acute lymphoblastic leukaemia.
Read More
NICE issues final draft guidelines for Novartis’ Kymriah
NICE has recommended a pioneering cancer treatment for people under the age of 25 with leukaemia in final draft guidelines.
Read More
NICE nod for Amgen’s rare leukaemia drug
Patients with a rare form of leukaemia look set to win routine access to a novel treatment option on the NHS in England and Wales after Amgen’s Blincyto was backed by cost watchdog NICE.
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
